“revolutionising healthcare through continuously
improving diagnostic solutions”
Randox Laboratories Limited
• Privately owned diagnostic and instrument company
• UK and Ireland’s largest indigenous diagnostic company
• Established in 1982
• Employs 850 people
• 200 scientists and engineers
We supply quality products to:
• Hospitals, clinical laboratories and veterinary and research
laboratories
• Over 130 countries
• An estimated 60,000 clients using Randox products.
In 2009:
• 4 billion diagnostic tests manufactured by Randox.
Our facilities may
have been basic
but we developed
excellent
diagnostic
products, many of
which we still
manufacture today!
Princess Royal Visit 1987
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
9
20 9
0
20 0
0
20 1
0
20 2
0
20 4
0
20 5
0
20 6
0
20 7
0
20 8
0
20 9
10
NUMBER OF STAFF
900
Staff Levels..
800
700
600
500
400
300
200
100
0
Current Product Range
• Biochip Array Technology (Including Molecular)
• Clinical Chemistry analysers and reagents
• Quality Control systems
• Life Sciences Department
• Randox Testing Services
• Randox Health Checks
We now have
60,000 customers worldwide
and have achieved significant market share
Miami-Dade County
California, USA
“We are very happy with the huge advantages that the
Evidence Investigator has brought to our death investigation
abilities.”
Dr Lee Hearn
Planned Population Federation of Korea (PPFK)
Seoul, South Korea
“I am very happy with the performance of
the Imola as my QC results from Korea's
national EQA scheme are always perfect
on the RX Imola.”
Randox Offices and Distributors
Collaborations Network
Randox has an extensive network of international collaborations
~
We collaborate with 35 universities and hospitals
in 7 different countries
~
Including Queen’s University Belfast and the University of Ulster
20th position out of the estimated 1,850
diagnostic companies worldwide
4th in QC serum and calibrators
Number 1 in supply to
international EQA schemes
Randox manufactures 8% of all clinical
chemistry tests in the world
Randox provides the reagents for 11% of
all HDL Cholesterol tests executed world
wide
Last year we manufactured our
40 billionth test
is a world class manufacturer !
PRODUCT PORTFOLIO
Innovation
Our mission statement:
“Revolutionising healthcare through
continuously improving diagnostic
solutions”
PRODUCT PORTFOLIO
Innovation
Products are designed and developed with
the customer and patient in mind
~
Our rigorous design and development process
ensures that all products are fit for purpose
Biochip Array Technology
Primary research
High throughput
Huge versatility of technology
Expanding portfolio
Complimentary clinical chemistry
Excellent QC throughout
Clinical
Randox has spent
$225million
developing Biochip Array Technology
Highly innovative…
. . with over 400 new
tests in development
– more than any other
company in the world
Randox Sales Conference October 2008
Randox in Cardiology
Cutting edge technology
and novel biomarkers to
accurately diagnose
patients with suspected
heart attacks
Randox has developed tests to
save 20% of patients lives
Respiratory Pathogen Biochip
Moraxella catarrhalis
Streptococcus pneumoniae
Influenza A
Influenza B
Staphylococcus aureus
Human Respiratory Syncytial virus A
Human Respiratory Syncytial virus B
Human parainfluenzavirus 1
Human parainfluenzavirus 2
Haemophilus influenzae
Human parainfluenzavirus 3
Mycoplasma penumoniae
Human parainfluenzavirus 4
Legionella pneumophila
Human coronavirus 229E/NL63
Chlamydophila pneumoniae
Human coronavirus OC43/HKU1
Human adenovirus B/C/E
Human metapneumovirus
Human rhinovirus A/B
Human bocavirus 1/2/3
Human enterovirus A/B/C
Randox 10-plex STI Biochip
Neisseria gonorrhoea (NG)
Chlamydia trachomatis (CT)
Trichomonas vaginalis (TV)
Mycoplasma genitalium (MG)
Ureaplasma urealyticum (UU)
Haemophilus ducreyi (HD)
9 patient samples hybridized in one carrier
Up to 54 samples run simultaneously
Treponema pallidum (TP)
Herpes simplex 1 (HSV1)
Mycoplasma hominis (MH)
Herpes simplex 2 (HSV2)
10 pathogens detected in
one PCR reaction!
Bladder Cancer
Development of
diagnostic
algorithm to
remove the
need for
cystoscopy
Breast Cancer RNA/cDNA array
Low density chip-based
cDNA arrays, using a
molecular signature panel
that can divide breast
tumours into clinically
relevant sub-types
•
•
•
•
•
•
One in nine women will be affected by breast cancer
Complex disease involving a number of sub groups
Sub-groups have treatment & prognostic significance
Current IHC methodology is not standardised
Interpretation of IHC can be problematic
IHC relies on small number of targets for diagnosis
Aim: to accurately subtype breast cancer
and predict outcome using a gene
expression array
Metabolic Syndrome
Defined as the Clustering of Cardiovascular Risk Factors
with 20-25% of adults affected
Metabolic Syndrome Arrays
I
II
Adiponectin
C-Peptide
C-reactive Protein (CRP)
Ferritin
Cystatin C
Insulin
Interleukin-1 alpha (IL-1α)
Interleukin-6 (IL-6)
Leptin
Plasminogen Activator Inhibitor-1 (PAI-1)
Resistin
Tumour Necrosis Factor-alpha (TNFα)
Co-morbidities of Metabolic Syndrome
•
•
•
•
•
•
•
•
•
•
•
•
Cardiomyopathy
Coronary Heart Disease
Atherogenic Dyslipidemia
Peripheral and Cerebrovascular Disease
Calcific Aortic Valvular Disease
Type 2 Diabetes
Polycystic Ovary Syndrome (PCOS)
Non-Alcoholic Fatty Liver Disease (NFALD)
Cognitive Impairment
Cancer
Chronic Kidney Disease
Mental Health Conditions
Applicability of other arrays to
metabolic conditions
Synergy with other
biochip arrays available
–
–
–
–
–
Adhesion molecules array
Cardiac arrays
Cerebral arrays
Cytokine arrays
Endocrine array
Ovarian Cancer RNA/cDNA array
Low density chip-based
cDNA arrays, using a
molecular signature
panel that can predict
responders and nonresponders to
chemotherapy (Taxol
and Platinum-based)
Ovarian Cancer RNA/cDNA array
• Low density chip-based cDNA array
• Predicts responders and non-responders to platinum and
taxol chemotherapies (using Ovarian tumours as models)
• Provides a rapid (1 day) test prior to treatment
• Ensures the patient gets the best treatment at the right time
• Standardised and easy to use protocols
Disease prediction – Cardiac disease risk
• Cardiovascular disease (CVD) is a complex multifactorial and
polygenic disorder
• Results from interaction between genetic makeup and environment
• Identification of SNPs in known CVD genes may therefore aid in the
identification of individuals at risk
• Use with Framingham score to better gauge patient risk
• This will permit lifestyle changes or target therapy
• Includes the best 20-SNP combination for prediction of cardiac
disease – derived from GWAS and meta analyses
Randox TxB Cardio®
Assay
Randox Health Checks
Due to the slowness of uptake of new tests
by the health service, we decided to
set up Randox Health Checks, our own clinic
Randox Health Checks
Conclusion
With the unravelling of the Human Genome Project – the potential
for life changing inventions is immense
~
We, at Randox, have developed the world’s most revolutionary
technology – in fact a disruptive technology in Laboratory
Medicine
~
We can help improve the lives of many people in this world
Belfast is as good a place to do this as anywhere in the world
~
We have a highly educated workforce open to the world
~
All we need is entrepreneurial leadership to overcome hurdles and
problems put in our way
~
Remember that Belfast has been the source of many inventions
and significant entrepreneurial endeavours
Henry George Ferguson
Ferguson designed and built a new plough
which was coupled to the tractor in
three-point linkage, so that both formed a
single unit. This 'Ferguson System',
building on the earlier two-point linkage
patented in 1919, was patented in 1928.
Together with many other inventions, it
was to revolutionise farming.
John Dunlop
Dunlop’s great invention, of the inner tube
for cycle tyres, came about more or less
by chance. In 1888 his small son was
prescribed cycling as cure for a heavy
cold; Dunlop hit on the idea of making
the boy's tricycle more comfortable by
fitting it with inflated tubes, made of
canvas and bonded together with liquid
rubber. He patented this idea, using the
word 'pneumatic' for the first time, in the
same year.
Invention is in our genes!
Thank you for listening…
“revolutionising healthcare through continuously
improving diagnostic solutions”